

Life Sciences

Brownstein's Life Sciences team of attorneys and public policy professionals helps pharmaceutical, medical device, biologics and genetics companies protect their ideas and increase their market share by providing comprehensive intellectual property, regulatory, corporate, policy, antitrust and business advice. They represent some of the world's most innovative companies.

Representative Matters

- Represented Fertility Lab Sciences, LLC in the formation of a new fertility laboratory joint venture and intellectual property licensing arrangement in Dallas-Fort Worth.
- Represented Fertility Lab Sciences, LLC in formation of a new fertility laboratory joint venture and intellectual property licensing arrangements in San Francisco.
- Represented Fertility Lab Sciences, LLC in formation of a new fertility laboratory joint venture and intellectual property licensing arrangements in Northern Virginia.
- Represented Fertility Lab Sciences, LLC in a joint venture transaction with Atlanta Center for Reproductive Medicine, LLC to form CCRM Atlanta, LLC.
- Represented Colorado Center for Reproductive Medicine, one of Colorado's leading fertility clinics, in a growth equity investment from TA Associates.
- On behalf of a health care technology company, generated congressional support for client's efforts to partner with federal departments and agencies, which ultimately led to an opportunity with the Department of Veterans Affairs.
- Represented Fertility Lab Sciences in formation of a new fertility laboratory joint venture in Minneapolis, Minnesota.
- Preserving consumer access to, and reducing incidents of abuse of, common ingredients in over-the-counter allergy and cold medications.
- Represented medical device manufacturer for protection of stents, valves, and catheters.
- Represented Breakthrough Products in its \$3.4 million convertible note purchase agreement.
- Brownstein represented Fertility Laboratories of Toronto, LLC in a joint venture transaction with Thomas Hannam Medicine Professional Corporation to establish Fertility Laboratories of Toronto Inc. and Fertility Surgical Centres of Toronto Inc.
- Brownstein represented Fertility Lab Sciences, LLC in a joint venture formation transaction.
- Represented a healthcare company in creating innovative new joint venture ownership structure for in vitro fertilization labs, leveraging best of breed technologies and best practices through licensing and management systems. Researched and created innovative corporate and business structure achieving business priorities while addressing competing requirements in areas of corporate, tax, insurance, consumer finance, and health care, including restrictions on corporate practice of medicine, fee splitting, self-referral, and anti-kickback.
- Working with Congressional committees of jurisdiction to challenge the Food and Drug Administration to apply more accurate risk/benefit profiles to needed therapies for obesity. Secured the introduction of and support for federal legislation to provide reimbursement for these therapies under the Medicare and Medicaid programs.
- Led the Coalition for Patient Safety and Medicine Integrity, a group of pharmaceutical, medical device and medical products companies, in developing the substance and strategy for passage of the SAFE DOSES Act, which modernized the criminal code to increase penalties for medical product cargo theft and provide law enforcement tools to deter and prosecute this criminal activity. At a time known for partisan gridlock in Congress, our Brownstein team successfully devised solutions for overcoming legislative paralysis,

resulting in one of the few new laws enacted by the 112th Congress.

- Represented Breakthrough Products, Inc. in their \$3 million Series B equity financing.
- Served as Nevada counsel to Apricus Biosciences, Inc. in connection with an underwritten public offering of common stock and warrants and issued opinions to the underwriters, the company and the company's transfer agent.
- Worked on behalf of a small biopharmaceutical company to ensure new Medicaid rules would not make it cost-prohibitive to provide its rare-disease medicine to Medicare recipients.
- On behalf of Z-Medica, a medical device company, worked to introduce the effectiveness of their product, QuikClot, to the military. QuikClot is now in widespread use in the military, in first responder and law enforcement units, and within various Homeland Security markets. The product is so effective that a military advisory committee recommended that all soldiers carry packets in their first-aid kits.
- During the health care reform debate, helped a major pharmaceutical company successfully advocate for a new FDA-approval pathway for follow-on biologic treatments in a way that preserves the United States' competitive edge in biotechnology while ensuring an appropriate balance between investment in new discovery and containing costs to patients.
- Nevada local counsel to Apricus Biosciences formerly known as Nexmed in the issue and sale of units of common stock and warrants.
- Represented Firehouse Ventures, LLC and its affiliates in the sale of all stock to VCA Animal Hospitals, Inc., a subsidiary of VCA Antech, Inc. Firehouse Ventures owned and operated six veterinary hospitals in the Denver metropolitan area.
- Assisted Aion Partners LLC in its corporate structuring and private placement of limited liability company units to raise equity for bringing its technology to market. Brownstein also secured the intellectual property rights for Aion to sell its proprietary, green technology that minimizes the occurrence of hospital-acquired secondary infections.
- Assisted a pharmaceutical company in obtaining appropriate reimbursement rates under new health reform law.
- In Health Care Reform, aided a major pharmaceutical company in its successful fight to preserve patent protection for costly, research intensive, biological pharmaceutical products.
- Represented Firehouse Ventures, LLC, a veterinary practice roll-up organization, in general business and corporate advisory legal matters. Brownstein helped to form the company, guided the founders through several rounds of equity and debt financings, and have provided employment, ERISA and benefits advice including phantom stock plans. Brownstein also handles all of Firehouse Ventures' litigation, real estate and practice acquisitions.
- Represented an artificial heart valve company in a \$20 million supply contract dispute resulting in favorable mitigation of client exposure and the eventual sale of the company to a major healthcare conglomerate.
- Negotiated two office leases in Boulder, Colorado for over 100,000 square feet of office and lab space on behalf of Gilead Sciences, a leading biopharmaceutical company.

Meet The Team

Michael W. King	Shareholder	T 303.223.1130	mking@bhfs.com
Peter M. Goodloe	Consulting Attorney	T 202.747.0506	pgoodloe@bhfs.com
Kevin A. Cudney	Shareholder	T 303.223.1166	kcudney@bhfs.com
Martha L. Fitzgerald	Shareholder	T 303.223.1472	mfitzgerald@bhfs.com
Lisa Hogan	Shareholder	T 303.223.1185	lhogan@bhfs.com

Brownstein Hyatt Farber Schreck

Elizabeth A. Maier	Policy Director	T 202.872.5299	emaier@bhfs.com
Robert P. Attai	Shareholder	T 303.223.1271	rattai@bhfs.com
Ryan J. Cudnik	Of Counsel	T 775.398.3813	rcudnik@bhfs.com
Sharon E. Caulfield	Shareholder	T 303.223.1110	scaulfield@bhfs.com
Ishra K. Solieman	Staff Attorney	T 303.260.1880	isolieman@bhfs.com
Joshua A. Weiss	Associate	T 303-223-1268	jweiss@bhfs.com
Martine Tariot Wells	Shareholder	T 303.223.1213	mwells@bhfs.com
Brian M. McKeon	Senior Policy Advisor	T 202.872.5283	bmckeon@bhfs.com
